Betta Pharmaceuticals Hits Day Low of CNY 50.06 Amid Price Pressure

Betta Pharmaceuticals Co., Ltd. experienced a notable decline today, with the stock dropping by 5.27% on June 16, 2026. The stock reached an intraday low of CNY 50.06, reflecting ongoing challenges in its market performance. Over the past year, Betta Pharmaceuticals has generated a return of -18.15%, significantly underperforming the China Shanghai Composite, which has seen a gain of 20.75% during the same period. In terms of financial metrics, the company has a market capitalization of CNY 20,232 million and a price-to-earnings ratio of 52.00, indicating a relatively high valuation compared to its earnings. The return on equity stands at 5.72%, while the price-to-book ratio is 2.98. Despite a dividend yield of 0.71%, the company's net sales have only grown at an annual rate of 15.17% over the last five years, with operating profit increasing at a rate of 9.21%. Overall, Betta Pharmaceuticals continues to face headwinds in its performance, as evidenced by its recent stock activity and long-term growth metrics.